Zacks Research Has Bullish Forecast for CORT Q4 Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Research analysts at Zacks Research upped their Q4 2024 earnings per share estimates for Corcept Therapeutics in a note issued to investors on Wednesday, November 20th. Zacks Research analyst K. Das now forecasts that the biotechnology company will post earnings of $0.28 per share for the quarter, up from their previous estimate of $0.26. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.31 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q3 2025 earnings at $0.41 EPS, Q4 2025 earnings at $0.52 EPS, FY2025 earnings at $1.56 EPS, Q3 2026 earnings at $0.70 EPS and FY2026 earnings at $2.38 EPS.

Several other brokerages also recently commented on CORT. HC Wainwright reissued a “buy” rating and issued a $80.00 price target on shares of Corcept Therapeutics in a report on Thursday, October 31st. Truist Financial boosted their target price on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a research report on Monday, September 30th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $38.00 price target on shares of Corcept Therapeutics in a report on Tuesday, July 30th. StockNews.com raised Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 31st. Finally, Piper Sandler raised their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, September 18th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $65.25.

Corcept Therapeutics Price Performance

CORT stock opened at $57.54 on Friday. The firm has a 50 day moving average of $48.41 and a 200-day moving average of $37.88. The firm has a market capitalization of $6.03 billion, a P/E ratio of 45.67 and a beta of 0.45. Corcept Therapeutics has a 12 month low of $20.84 and a 12 month high of $61.66. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01.

Corcept Therapeutics (NASDAQ:CORT) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The business had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. During the same quarter last year, the company earned $0.28 EPS. The firm’s revenue was up 47.7% compared to the same quarter last year.

Hedge Funds Weigh In On Corcept Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CORT. Vanguard Group Inc. increased its holdings in Corcept Therapeutics by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 9,565,782 shares of the biotechnology company’s stock valued at $240,962,000 after purchasing an additional 28,250 shares during the period. State Street Corp raised its holdings in shares of Corcept Therapeutics by 0.6% during the third quarter. State Street Corp now owns 3,519,263 shares of the biotechnology company’s stock valued at $162,871,000 after acquiring an additional 19,893 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Corcept Therapeutics by 4.2% in the second quarter. Dimensional Fund Advisors LP now owns 2,676,335 shares of the biotechnology company’s stock worth $86,952,000 after acquiring an additional 108,658 shares during the period. Geode Capital Management LLC boosted its holdings in Corcept Therapeutics by 4.4% in the third quarter. Geode Capital Management LLC now owns 2,378,758 shares of the biotechnology company’s stock valued at $110,108,000 after acquiring an additional 99,470 shares in the last quarter. Finally, FMR LLC boosted its holdings in Corcept Therapeutics by 24.6% in the third quarter. FMR LLC now owns 1,363,922 shares of the biotechnology company’s stock valued at $63,122,000 after acquiring an additional 269,074 shares in the last quarter. 93.61% of the stock is owned by institutional investors.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, insider Gary Charles Robb sold 11,000 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $46.28, for a total transaction of $509,080.00. Following the completion of the sale, the insider now directly owns 22,772 shares in the company, valued at $1,053,888.16. This represents a 32.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider William Guyer sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $35.30, for a total value of $353,000.00. Following the completion of the sale, the insider now directly owns 6,039 shares of the company’s stock, valued at approximately $213,176.70. This trade represents a 62.35 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 36,301 shares of company stock worth $1,594,253. 20.50% of the stock is currently owned by corporate insiders.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.